Dated: June 1, 1995.

Roger Patterson,

Regional Director, Mid-Pacific Region.

[FR Doc. 95–13987 Filed 6–7–95; 8:45 am]

BILLING CODE 4310–94–M

INTERSTATE COMMERCE COMMISSION

[Ex Parte No. 388 (Sub-No. 1)]

Intrastate Rail Rate Authority—Alabama

AGENCY: Interstate Commerce Commission.

ACTION: Notice of provisional recertification.

SUMMARY: The State of Alabama has filed an application for recertification. The Commission, under *State Intrastate Rail Rate Authority*, 5 I.C.C.2d 680, 685 (1989), provisionnally recertifies the State of Alabama to regulate intrastate rail rates, classifications, rules, and practices. After its review, the Commission will issue a recertification decision or take other appropriate action.

DATES: This provisional recertification will be effective on June 8, 1995.

FOR FURTHER INFORMATION CONTACT: Elaine Sehrt-Green, (202) 927–5269 or Beryl Gordon, (202) 927–5610 [TDD for hearing impaired: (202) 927–5721].

Decided: June 1, 1995.

By the Commission, David M. Konschnik, Director, Office of Proceedings.

Vernon A. Williams,

Secretary.

[FR Doc. 95–14057 Filed 6–7–95; 8:45 am]

BILLING CODE 7035–01–P

JUDICIAL CONFERENCE OF THE UNITED STATES

Proposed Long Range Plan for the Federal Courts

AGENCY: Judicial Conference of the United States.

ACTION: Notice of Conference actions concerning the Proposed Long Range Plan for the Federal Courts.

On March 14, 1995, the Judicial Conference of the United States received from its Committee on Long Range Planning a Proposed Long Range Plan for the Federal Courts. The Proposed Plan is similar in format and content to the tentative proposal that the Committee circulated to the public last November (59 FR 55704) but contains changes made by the Committee to reflect comments received in writing and at public hearings with respect to the earlier version.

In receiving the Proposed Plan, the Judicial Conference authorized public distribution of the document and took the following actions regarding the provisions of the Plan:

1. The Conference allowed its individual members until April 11, 1995, to request referral of any specific numbered recommendations to the appropriate Conference committees for further study and report to the September 1995 Conference session.

2. The Conference approved, effective April 12, 1995, all recommendations in the Proposed Plan not subsequently identified for further study and report as described above. Approval of a Plan recommendation includes the corresponding implementation strategies but not the supporting commentary.

In accordance with this procedure, the following items were approved, effective April 12, 1995, as part of the Long Range Plan for the Federal Courts:

Recommendations	Implementation strategies
19	
21	
26	
31	
32	32a–32b.
34	
35	35a–35d.
36–38	
39	39a, 39d–39e.
40–41	
43	
45	45a–45b.
46	46a–46b.
47	
50–51	
53	53a–53b.
54–57	
58	58a–58b.
59–62	
63	63a–63d.
64	
69	
71	
77–80	
81	81a–81b.
82–88	
91	91a–91c.
93	93a–93e.
94	94a–94c.
95	
97	
99	99a–99e.
100–101	

Also, in accordance with the prior decision of the Judicial Conference, individual Conference members requested that Conference action on the following items in the Proposed Plan be deferred pending further study by the appropriate committees:

Recommendations	Implementation strategies
1–3	
4	4a–4c.
5–8	
9	9a–9b.
10–11	
12	12a–12c.
13–15	
16	16a–16c.
17–18	
20	
22–25	
27	
28	28a–28b.
29	
30	30a–30c.
33	
	39b–39c.
42	42a–42b.
44	44a.
	45c.
48	
49	49a–49b.
52	52a–52c.
65–68	
70	70a–70c.
72–76	
89	
90	
92	92a–92g.
	94d.
96	
98	

Because most of the deferred items involve policy issues, they were assigned to the Conference committees with responsibility for the programs or topics in question and will be the subject of reports at the September 1995 Conference session. The Conference's Executive Committee was also assigned to consider the 11 recommendations (1–3, 5–6, 9, 11, 16, 30 76, 98) and one implementation strategy (39b) on which purely technical questions were raised. After consulting with Conference members, the Executive Committee, on May 31, 1995, approved those 12 items on the Conference's behalf with minor word changes intended to clarify, improve accuracy, or adjust tone without altering substantive meaning.

The Long Range Plan is a guide to policy making and administrative action by the Conference and other judicial branch authorities. However, only those items approved by the Judicial Conference represent Conference policies. All commentary on recommendations and implementation strategies and all other Plan provisions (including the recommendations and implementation strategies on which Conference members have requested further study) merely reflect the views of the Committee on Long Range Planning unless expressly approved by the Conference in subsequent proceedings.

FOR FURTHER INFORMATION CONTACT: Long Range Planning Office, Administrative Office of the United States Courts, Suite 4–170, One Columbus Circle, N.E., Washington, D.C. 20544, 202–273–1810.

Dated: June 1, 1995.

L. Ralph Mecham,

Secretary to the Judicial Conference of the United States.

[FR Doc. 95–14056 Filed 6–7–95; 8:45 am]

BILLING CODE 2210–01–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated April 4, 1995, and published in the **Federal Register** on April 12, 1995, (60 FR 18617), Games Chemicals, Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Methylphenidate (1724)	II
Amobarbital (2125)	II
Pentobarbital (2270)	II
Secobarbital (2315)	II
Glutethimide (2550)	II
Methadone (9250)	II
Methadone-intermediate (9254)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II

Two registered manufacturers filed a written request for a hearing with respect to Methylphenidate (1724). A third registered manufacturer filed a comment that the firm wishes to participate if a hearing is requested for Methylphenidate. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, Section 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted with the exception of Methylphenidate (1724).

Dated: May 31, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–13996 Filed 6–7–95; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 5, 1995, Radian Corporation, P.O. Box 201088, Mopac Blvd., Austin, Texas 78720, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480)	I
Aminorex (1585)	I
4-Methylaminorex (cis isomer) (1590).	I
Methaqualone (2565)	I
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I
3,4-Methylenedioxyamphetamine (7400).	I
3,4-Methylenedioxy-N-ethyl-amphetamine (7404).	I
3,4-Methylenedioxymeth-amphetamine (7405).	I
4-Methoxyamphetamine (7411)	I
Psilocybin (7437)	I
Psilocyn (7438)	I
Dihydromorphine (9145)	I
Normorphine (9313)	I
Acetylemthadol (9601)	I
Alphacetylmethadol except Levo-Alphacetylmethadol (9603).	I
Normethadone (9635)	I
3-Methylfentanyl (9813)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Methylphenidate (1724)	II
Amobarbital (2125)	II
Pentobarbital (2270)	II
Secobarbital (2315)	II
Phencyclidine (7471)	II
1-Piperidinocyclohexanecarbonitrile (8603).	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Diphenoxylate (9170)	II
Benzoylecgonine (9180)	II
Ethylmorphine (9190)	II
Hydrocodone (9193)	II
Isomethadone (9226)	II
Meperidine (9230)	II
Methadone (9250)	II
Methadone-intermediate (9254)	II
Morphine (9300)	II
Levo-alphacetylmethadol (9648)	II
Oxymorphone (9652)	II
Alfentanil (9737)	II
Sufentanil (9740)	II
Fentanyl (9801)	II

The firm plans to manufacture deuterated and non-deuterated analytical reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application and may also file a written request for a hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. Federal Register Representative (CCR), and must be filed no later than July 10, 1995.

Dated: May 31, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–13995 Filed 6–7–95; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 24, 1995, Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360)	I
Cocaine (9041)	II

The Institute will manufacture Marihuana cigarettes for the National Institute on Drug Abuse (NIDA) and the Cocaine will be used for reference standards, human and animal research, as dictated by NIDA.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application and may also file a written request for a hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice,